BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII

• Main Authors: KOPACZ Kristopher, KENNISTON Jon A, ADELMAN Burt, KASTRAPELI Niksa, CONLEY Gregory P, NIXON Andrew, LINDBERG Allison P, COMEAU Stephen R, MASON Shauna
• Format: Patent
• Language: English; Spanish
• Published: 25.01.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis. One aspect of the present disclosure is a bispecific antibody, comprising: a first polypeptide that comprises a light chain of a first antibody, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL) (e.g., a kappa light chain or a lambda light chain); and a second polypeptide that comprises a heavy chain of the first antibody, the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH). Se describen en la presente anticuerpos biespecíficos que se unen a la calicreína (pKal) y Factor XII del plasma y métodos para producir y usar tales anticuerpos bi-específicos para tratar enfermedades y trastornos asociados con el sistema de contacto, por ejemplo, angioedema hereditario o trombosis. Un aspecto de la descripción actual es un anticuerpo biespecífico, que comprende: un primer polipéptido que comprende una cadena ligera de un primer anticuerpo, la cadena ligera comprende una región variable de cadena ligera (VL) y una región constante de cadena ligera (CL) (por ejemplo, una cadena ligera kappa o una cadena ligera lambda); y un segundo polipéptido que comprende una cadena pesada del primer anticuerpo, la cadena pesada comprende una región variable de cadena pesada (VH) y una región constante de cadena pesada (CH).